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Background: Magnetic resonance imaging (MRI)-guided vacuum-assisted biopsy is the technique of choice for
lesions that are visible only with breast MRI. The purpose of this study was to report our clinical experience with
MRI-guided vacuum-assisted biopsy in Korean women.
Methods: A total of 13 patients with 15 lesions for MRI-guided vacuum-assisted biopsy were prospectively entered
into this study between September 2009 and November 2011. Biopsy samples were obtained in a 3-T magnet
using a 9-guage MRI-compatible vacuum-assisted biopsy device. We evaluated clinical indications for biopsy, lesion
characteristics on prebiopsy MRI, pathologic results, and postbiopsy complication status.
Results: The clinical indications for MRI-guided vacuum-assisted biopsy were as follows: abnormalities in patients
with interstitial mammoplasty on screening MRI (n = 10); preoperative evaluation of patients with a recently
diagnosed cancer (n = 3); and suspicious recurrence on follow-up MRI after cancer surgery (n = 1) or chemotherapy
(n = 1). All lesions have morphologic features suspicious or highly suggestive of malignancy by the American
College of Radiology Breast Imaging Reporting and Data System category of MRI (C4a = 12, C4b = 2, C5 = 1). In
two of the 15 lesions (13.3%, <6 mm), MRI-guided 9-gauge vacuum-assisted breast biopsy was deferred due to
nonvisualization of the MRI findings that led to biopsy and the lesions were stable or disappeared on follow up so
were considered benign. Of 13 biopsied lesions, pathology revealed four malignancies (4/13, 30.8%; mean size
15.5 mm) and nine benign lesions (9/13, 69.2%; size 14.2 mm). Immediate postprocedural hematoma (mean size
23.5 mm) was observed in eight out of 13 patients (61.5%) and was controlled conservatively.
Conclusions: Our initial experience of MRI-guided vacuum-assisted biopsy showed a success rate of 86.7% and a
cancer diagnosis rate of 30.8%, which was quite satisfactory. MRI-guided vacuum-assisted breast biopsy is a safe
and effective tool for the workup of suspicious lesions seen on breast MRI alone without major complication. This
biopsy may contribute to the early diagnosis of breast cancer in interstitial mammoplasty patients in Korea.Background
Magnetic resonance imaging (MRI) of the breast is the
most sensitive technique for the detection, diagnosis,
and treatment planning of breast cancer with a high sen-
sitivity of 90 to 99%. Although MRI has a high sensitivity
in detecting breast lesions, its specificity is comparatively
low, ranging from 37 to 72% [1]. Because of the limited
specificity of MRI, histopathological verification is required* Correspondence: lionmain@catholic.ac.kr
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reproduction in any medium, provided the orto avoid unnecessary surgical biopsies of benign lesions
detected by MRI.
The increasing use of MRI yields a number of MRI-
only visible suspicious lesions that cannot be identified
by mammography or ultrasonography. A MRI-guided
tissue sampling method (MRI-guided percutaneous core
biopsy or vacuum-assisted biopsy) is the technique of
choice for lesions that are visible only on breast MRI,
and it has been performed successfully for many years in
the western countries [2-12]. In contrast, second-look
ultrasound and ultrasound-guided tissue sampling is
usually performed in Korea, and MRI-guided tissue sam-
pling is only performed at a few university hospitals.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
An et al. World Journal of Surgical Oncology 2013, 11:200 Page 2 of 7
http://www.wjso.com/content/11/1/200Except for the recently published preliminary experi-
ence with MRI-guided vacuum-assisted breast biopsy
(VABB) in Japan [13-15], there are no published data in
Asian or Korean women. The aim of this prospective
study was therefore to evaluate our initial clinical experi-
ence with MRI-guided VABB of breast lesions visible
only on MRI in Korean women. We report our initial
clinical experience in 15 cases scheduled for MRI-guided
9-gauge VABB of MRI-detected lesions interpreted as
suspicious or highly suggestive of malignancy.
Methods
Patient population
This was a prospective study for assessing the usefulness
of MRI-guided VABB, approved by the Institutional
Review Board of our hospital. Informed consent was
obtained from all patients. A total of 13 patients with
15 lesions scheduled for MRI-guided VABB and surgicalTable 1 Clinical indications, lesion characteristics on prebiops
in 15 lesions




1 Interstitial mammoplasty, screening Mass 22 Lob
rim
2 Interstitial mammoplasty, screening Mass 14 Lob
hom
3 Interstitial mammoplasty, ipsilateral
breast cancer, chemotherapy follow-up
Mass 8 Irreg
hom
4 Interstitial mammoplasty, screening Mass 18 Irreg
hete
5 Interstitial mammoplasty, screening Mass 26 Lob
hete
6 Interstitial mammoplasty, screening Mass 8 Irreg
hom
7 Interstitial mammoplasty, screening Mass 5 Rou
hom
8 Interstitial mammoplasty, screening Mass 28 Lob
hete
9 Interstitial mammoplasty, screening Mass 16 Ova
hete
10 Interstitial mammoplasty, screening Mass 6 Ova
hom
13 Interstitial mammoplasty, screening Mass 9 Ova
hete
11 Breast cancer, preoperative staging Mass 8 Ova
hete
12 Breast cancer follow-up Nonmass 11 Foc
14 Breast cancer, preoperative staging Mass 6 Ova
hete
15 Breast cancer, preoperative staging Nonmass 5 Seg
hete
BI-RADS American College of Radiology Breast Imaging Reporting and Data System,
IDC invasive ductal carcinoma, MRI magnetic resonance imaging, NA not available,excision between September 2009 and November 2011
were asked to participate in this prospective study. The
patients ranged in age from 35 to 73 years and the median
age was 51.4 years.Breast MRI technique and lesion characteristics before
biopsy
The MRI scans were acquired with the patient in the
prone position with a 1.5 T scanner (Achieva; Philips
Medical Systems, Best, the Netherlands) equipped with a
breast coil.
The MRI images with the Achieva scanner were
acquired using the following sequences: sagittal, fat-
suppressed, and fast spin-echo T2-weighted imaging
sequence (Repetition time/echo time 6,000/100 ms, flip
angle 90°, 30 slices, field of view of 320 mm, matrix 424 ×
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C4a MRI FU NA
DCIS ductal carcinoma in situ, FA fibroadenoma, FCC fibrocystic change,
VABB vacuum-assisted breast biopsy.
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56 seconds) and precontrast and postcontrast dynamic
axial T1-weighted three-dimensional, fat-suppressed, fat-
spoiled gradient-echo sequence (Repetition time/echo
time 6.9/3.4, flip angle of12°, 2.0 mm slice thickness with
no gap, acquisition time of 1 minute 31 seconds). The im-
ages were obtained before and at 0, 91, 182, 273, 364, and
455 seconds after a rapid bolus injection of gadolinium–
diethylenetriamine pentaacetic acid (Magnevist; Schering,
Berlin, Germany) at 0.1 mmol/kg of body weight.
Two breast radiologists analyzed the imaging findings
according to the American College of Radiology Breast
Imaging Reporting and Data System categories for MRI
[16]. All lesions were classified into category 4 or cat-
egory 5 on MRI. For all cases, the following lesion char-
acteristics were recorded: type (focus, mass or nonmass
enhancement), size, location, and kinetic analysis.Figure 1 Example of invasive ductal carcinoma after silicone injection
had a suspicious lesion in the left breast on magnetic resonance imaging (
image showing clustered, lobular, rim-enhancing masses with relatively sm
College of Radiology Breast Imaging Reporting and Data System category
immediately before biopsy showing clustered enhancing masses. (C) Axial
presence of the obturator (arrow) within the mass. (D) Axial T1-weighted s
MRI-guided vacuum-assisted biopsy showing air and hematoma at the bioMRI-guided vacuum-assisted breast biopsy procedure
Biopsies were performed with a 9-gauge MRI-compatible
vacuum-assisted biopsy device (Automated Tissue Exci-
sion and Collection; Suros Surgical Systems, Indianapolis,
IN, U.S). All biopsies were performed by two radiologists
specializing in breast imaging (BJK, SHK); all had previous
experience in breast MRI and percutaneous biopsies under
stereotactic and sonographic guidance. The two radiolo-
gists had not previously performed the procedure but had
observed or assisted one or more of the experienced
radiologists.
The MRI biopsy technique has been previously de-
scribed in detail [9]. The patient was positioned prone in
the 1.5 T magnet (Signa, GE Medical Systems, Milwaukee,
WI, USA). The affected breast was placed in a dedicated
biopsy compression device using a commercially available
grid localizing system. The protocol for MRI-guided VABBin the breast. A 73-year-old woman who received silicone injection
MRI) screening. (A) Axial and sagittal contrast enhanced T1-weighted
ooth margins in the left breast, which were categorized into American
4b. (B) Axial T1-weighted subtracted dynamic image acquired
T1-weighted subtracted dynamic image of the left breast showing the
ubtracted dynamic image of the left breast immediately after 9-gauge
psy site. Histologic analysis demonstrated invasive ductal carcinoma.
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targeting images (breast compression by the biopsy guid-
ance grid, marking the expected lesion site with a fiducial
marker on the skin, and a sagittal T1 fat-saturated three-
dimensional spoiled gradient echo image before and
after intravenous administration of 20 ml gadodiamide
(Omniscan; GE Healthcare, Oslo, Norway) plus 10 ml
saline); step 2, determining lesion location and desired
depth of probe insertion; step 3, preparing the probe;
step 4, placing the device, and performing imaging to con-
firm the lesion location (sterilization and anesthetization
of the breast, placement of the introducer and stylet
through the needle guide, removal of the stylet and place-
ment of the obturator inside the introducer, and axial scan
to confirm accurate targeting); step 5, performing the
biopsy, postexamination images and collecting the speci-
mens (removal of the obturator and insertion of the biopsy
device, tissue sampling, and post-biopsy sagittal scan toFigure 2 Example of ductal carcinoma in situ after silicone injection in
had a suspicious lesion in the left breast on magnetic resonance imaging (
on the inversion recovery MRI with chemically selective water suppression.
showing irregular, speculated, heterogeneous enhancing mass, which was
Reporting and Data System category 5. (C) Dynamic time-intensity curves o
washout (type III). (D) Sagittal T1-weighted subtracted dynamic image of th
Histologic analysis demonstrated ductal carcinoma in situ.assess the completeness of tissue acquisition and to
examine for the presence of postprocedural complica-
tions); and step 6, post-biopsy care of the breast (com-
pression with ice and application of a sterile dressing on
the biopsy site).Data analysis
Data collection – including clinical indications for breast
MRI, patient age, menopausal status, lesion size and type
on MRI, biopsy parameters, histologic results of vacuum-
assisted biopsy and surgical excision, and complications –
was performed by reviewing medical records. The time of
the biopsy (minutes) was determined by calculating the
interval between the beginning of the MRI localizing se-
quence and the end of the final MRI sequence acquired.
The radiologist performing the biopsy reviewed the MRIs
obtained during and after the biopsy to determine thethe breast. A 44-year-old woman who received silicone injection
MRI) screening. (A) Silicone granulomas showing high signal intensities
(B) Sagittal T1-weighted subtracted dynamic image of the left breast
categorized into American College of Radiology Breast Imaging
f the lesion showing an initial fast uptake followed by a delayed
e left breast showing the obturator tip (arrow) within the mass.
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whether the MRI target was sampled or possibly excised.
Results
Clinical indications for MRI-guided vacuum-assisted
breast biopsy
The clinical indications for MRI-guided VABB were
as follows: abnormalities in patients with interstitial
mammoplasty on screening MRI (n = 10); presurgical
evaluation of patients who were recently diagnosed
with cancer (n = 3); and suspected recurrence on
follow-up MRI after cancer surgery (n = 1) or chemo-
therapy (n = 1). None of the 15 lesions that were seen
on MRI were detected by mammography, diagnostic or
second-look ultrasonography.
Lesion characteristics on pre-biopsy MRI
The MRI-detected lesions included 13 masses and two
nonmass enhancements. The mean diameter of lesionsFigure 3 Example of silicone mastitis after silicone injection in the br
suspicious lesion in the left breast on magnetic resonance imaging (MRI) sc
oval, smooth, heterogeneous enhancing mass in the left breast, which was
Reporting and Data System category 4a. (B) Dynamic time-intensity curves
in the delayed phase (type III). (C) Sagittal, T1-weighted subtracted dynami
enhancing mass in the 12:00 hours position. (D) Sagittal T1-weighted subtr
showing low signal within the lesion (arrow), indicating the location of the
immediately after completion of tissue acquisition showing hematoma form
silicone mastitis.on prebiopsy MRI was 1.27 mm (range, 5 to 28 mm).
The clinical indications and MRI features with kinetic
analysis of 15 lesions are summarized in Table 1. All
lesions had morphologic features suspicious or highly
suggestive of malignancy according to the American
College of Radiology Breast Imaging Reporting and Data
System category of MRI (C4a = 12, C4b = 2, C5 = 1).
Biopsy procedure and histopathologic results
MRI-guided VABB was successfully performed in 13 of
15 lesions (86.7%). In two lesions (13.33%), MRI-guided
VABB could not be performed because the lesions
disappeared on the scheduled day of biopsy. The mean
procedural time was 55.7 minutes (range 20 to 90 mi-
nutes). An average number of nine specimens were
obtained per lesion (range, 6 to 11).
Histopathological results of the VABB and findings of
the surgical specimens are summarized in Table 1. Of the
13 lesions sampled, four lesions were malignant (30.8%,east. A 47-year-old woman who received silicone injection had a
reening. (A) Axial contrast enhanced T1-weighted image showing
categorized into American College of Radiology Breast Imaging
of the lesion showing an initial fast uptake followed by a fast washout
c image acquired immediately before biopsy showing heterogeneously
acted dynamic image acquired after placement of the obturator
obturator tip. (E) Sagittal T1-weighted subtracted dynamic image
ation at the biopsy site. Histologic analysis demonstrated
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lesions were benign (69.2%, 9/13) (Figure 3).
Among the cases of confirmed malignancies, three le-
sions were invasive ductal carcinoma (Figure 1) and one
was ductal carcinoma in situ (Figure 2). All cancers diag-
nosed by VABB were the mass type of enhancement.
Malignant lesions diagnosed by VABB were surgically
excised in three out of four cases. One patient did not
undergo surgery due to bone metastasis detected by
bone scan and positron emission tomography–computed
tomography. Residual cancer was found at surgery in
two out of three patients. One patient, in whom the
MRI target was considered to have been completely ex-
cised, had no residual lesion. All benign diagnoses were
confirmed by imaging–histologic correlation and by
follow-up MRI at 6 to 12 months after biopsy. There
were no missed cancers in the patients having benign le-
sions with concordant histology on MRI-guided biopsy.
Lesions with deferred biopsy
There were two lesions in which the biopsy was deferred.
The lesion type was foci measuring 4 mm and a small
mass measuring 6 mm on the initial MRI (Figure 4).
Follow-up MRI within 6 months revealed resolution or
decrease in the size of the lesions.
Postbiopsy complications
MRI performed immediately after biopsy showed that
complete removal of the target lesion was achieved inFigure 4 A 38-year-old woman with breast cancer on preoperative m
enhanced T1-weighted image showing oval, smooth, heterogeneous enha
categorized into American College of Radiology Breast Imaging Reporting
curves of the lesion showing an initial fast uptake followed by a fast washo
category 4a. (C) Sagittal, contrast enhanced T1-weighted image on the day
resonance imaging-guided breast biopsy was cancelled.one patient (7.7%), partial removal of the target lesion
was achieved in seven patients (53.8%), and there was
difficulty in assessing the removal of the target lesion
due to bleeding in five patients (38.5%).
Postprocedural hematoma formation was observed in
eight patients (61.5%), and was controlled conservatively.
The mean size of the hematoma was 23.5 mm (range, 21
to 28 mm). Postprocedural defect was observed in three
patients and the mean size of the defect was 14.3 mm
(range, 11 to 18 mm). Other complications (significant
bleeding, infection, vasovagal reaction, contralateral skin
piercing) were not observed.
Discussion
This study reports our early experience with MRI-
guided VABB. We had no prior experience in MRI-
guided VABB. Our initial experience showed that the
success rate of MRI-guided VABB was 86.7% (13/15).
This rate is slightly lower than the 96 to 100% technical
success rates reported in prior studies of MRI-guided
VABB [6-9,11,12,14]. The median procedural time in
our study was 55.7 minutes. The median time of MRI-
guided VABB with the same device in prior studies
ranged from 30 to 38 minutes. MRI-guided VABB re-
vealed cancer in four of 13 cases (30.8%), similar to prior
clinical reports of this method. Potential failure of MRI-
guided VABB were mainly due to the nonvisualization of
lesions on the day of biopsy, which may have been
caused by changes in the hormonal status or probablyagnetic resonance imaging for staging. (A) Sagittal, contrast
ncing mass in the right breast, measuring 6 mm, which was
and Data System (BI-RADS) category 4a. (B) Dynamic time-intensity
ut in the delayed phase (type III), which was categorized into BI-RADS
of biopsy showing no suspicious lesions, and hence magnetic
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ing biopsy. On gaining experience, MRI-guided VABB
can be performed in an even shorter amount of time
and can have a higher technical success rate than that
reported in this study.
Compared with previous reports of studies on MRI-
guided VABB, our study included a higher proportion of
interstitial mammoplasty cases (11 out of 15, 73.3%),
which has not been reported previously (Figure 1, Figure 2
and Figure 3). The malignancy rate in 11 interstitial
mammoplasty cases was 36.4% (4/11), and the mean size
of detected cancer was 1.5 mm (range, 8 to 22 mm). Pa-
tients who had received silicone or paraffin injection could
not be easily or properly evaluated by palpation, mam-
mography, or sonography. As a consequence, breast can-
cers in patients with interstitial mammoplasty were
detected at an advanced stage. Dynamic breast MRI is the
modality of choice to detect breast cancer, and MRI-
guided biopsy is the only method that can confirm suspi-
cious enhancing breast lesions in these patients. According
to our previous study [17], the mean diameter of the
detected cancers in these patients was 5.5 cm (range 4.8 to
7.1 cm). In this study, cancers diagnosed by MRI-guided
VABB were smaller in size and at an earlier stage com-
pared with those in our previous publication.
The present study has some limitations. The main
limitation of this study was the small number of cases.
Another limitation was the short period of follow-up in
some cases (14 to 35 months) with benign lesions.
Thirdly, we did not correlate the hormonal status of the
patient and the lesion visibility on MRI. A better ap-
proach would be to obtain the patient’s menstrual his-
tory and usage of hormone replacement therapy before
MRI examination.
Conclusions
MRI-guided VABB is a safe, efficient and effective tool
without any major complications in Korean women.
During our initial experience a success rate of 86.7%
was achieved, which was quite satisfactory. MRI-guided
VABB may contribute to the early diagnosis of breast
cancer in interstitial mammoplasty patients in Korea.
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